Accutane's Pregnancy Risk: Are Women Aware?
Researchers Find Some Women May Not Have Heard About Birth Defects Linked to Acne Drug
WebMD News Archive
Oct. 14, 2005 -- Some women apparently aren't getting the message that they
shouldn't take the acne drug Accutane and its generic versions during
Accutane and its generic versions are an effective acne treatment, but
they're not intended for use during pregnancy due to the risk of birth
That well-publicized risk is stressed in information from the drug's makers.
to try to prevent pregnant women
from taking Accutane or its generic versions.
The drug's old pregnancy prevention program was voluntary. It wasn't always
heeded, a new report shows.
The researchers included Julia Robertson of the Birth Defects and Genetics
Program in Utah's health department. Their findings appear online in Birth
Defects Research (Part A): Clinical and Molecular Teratology.
Pregnant and at Risk
The report included 34 women who had taken Accutane or its generic versions
while pregnant. Between April 2002 and September 2004, the women had
voluntarily called a hotline run by the Organization of Teratology Information
A teratogen is a substance that causes birth defects.
Many of the women said they didn't remember hearing or following the old
For instance, the old program recommended that women get birth control
counseling and two negative pregnancy tests before starting the drug.
Eight women said they didn't remember being counseled about birth control,
and 25 said they hadn't gotten a second pregnancy test before taking the
Also, the program advised monthly pregnancy tests while women took the drug.
More than half said they hadn't done that. The drug is usually taken for four
to six months.
In addition, few women reported having the type of severe acne for which the
drug is intended.
It's possible that the women's reports weren't accurate. There's also no
information on women for whom the old program worked since they didn't have a
reason to call the birth defects hotline.
The new program, announced by the FDA in August, is called
The iPLEDGE plan requires virtually everyone involved with prescribing,
supplying, or using the drug to register and accept certain